The global continuous bioprocessing market size was valued at USD 386.89 million in 2025 and is projected to grow from USD 453.67 million in 2026 to USD 1,641.09 million by 2034, registering a CAGR of 17.44% during the forecast period (2026–2034). North America dominated the continuous bioprocessing market with a market share of 38.65% in 2025.
Continuous bioprocessing is an advanced biomanufacturing approach that integrates upstream and downstream operations into a continuous production workflow for biologics, including monoclonal antibodies, vaccines, recombinant proteins, and cell therapies. It enables uninterrupted manufacturing, enhances process efficiency, and optimizes facility utilization. The technology supports scalable production while maintaining high product quality and regulatory compliance.
The continuous bioprocessing market demand is driven by the rising biologics production, growing investments in biopharmaceutical manufacturing, and the need for cost-efficient, high-productivity processes. Manufacturers are adopting advanced automation, single-use technologies, and integrated systems, driving continuous bioprocessing market growth.
Download a Free Sample to Explore Detailed Market Insights
A major trend in the continuous bioprocessing market is the increasing adoption of AI-driven digital twin technology to optimize biologics manufacturing in real time. Manufacturers are shifting from periodic process monitoring to predictive, data-driven control that continuously simulates production conditions, enabling rapid parameter adjustments, reducing batch deviations, and improving product consistency. For example, Sartorius has expanded digital bioprocessing solutions that combine advanced analytics with process automation to enhance continuous manufacturing performance across commercial biologics facilities.
Another significant trend is the transition from isolated continuous unit operations to fully integrated end-to-end continuous bioprocessing platforms. Biopharmaceutical manufacturers are connecting upstream perfusion, continuous chromatography, virus inactivation, filtration, and formulation processes into unified manufacturing workflows to reduce production time, increase facility utilization, and lower operational costs. For example, Thermo Fisher Scientific offers integrated continuous bioprocessing solutions combining upstream, downstream, and analytical technologies to support scalable commercial biologics manufacturing.
The continuous bioprocessing market forecasts continued investment activity driven by increasing demand for efficient biologics manufacturing, process automation, and scalable production technologies. Companies are expected to prioritize investments in continuous upstream and downstream processing platforms, digital bioprocess control systems, and manufacturing capacity expansion to improve productivity and reduce production costs.
Key Investment and Funding Activities in Continuous Bioprocessing Market, 2026
Biocon Ltd.
USD 460 Million
In January 2026, Biocon completed a USD 460 million Qualified Institutions Placement (QIP). The proceeds will strengthen the company's biopharmaceutical manufacturing capabilities and strategic growth initiatives.
Antheia
USD 24 Million
In January 2026, Antheia raised an additional USD 24 million to complete its Series C financing, bringing funding secured over the previous year to more than USD 175 million. The capital will expand commercial biomanufacturing capacity and establish US manufacturing operations for biosynthetic pharmaceutical ingredients.
Trailhead Biosystems
USD 20 Million
In January 2026, Trailhead Biosystems secured USD 20 million to commercialize iPSC-derived human cell products and manufacturing media used in advanced bioprocess development.
Growing Biologics Pipeline and Rising Adoption of Integrated Continuous Manufacturing Drives Market
The increasing number of monoclonal antibodies, recombinant proteins, vaccines, and advanced biologics entering clinical and commercial production is driving demand for continuous bioprocessing technologies. Biopharmaceutical manufacturers require highly productive and scalable manufacturing platforms to meet rising global biologics demand while maintaining consistent product quality. Continuous bioprocessing enables higher facility throughput, reduced manufacturing footprints, and lower production costs compared with conventional batch processes. Thus, increasing biologics production continues to drive market growth.
The growing transition toward integrated continuous manufacturing is accelerating demand for advanced bioprocessing equipment, automation platforms, and single-use technologies across the biopharmaceutical industry. Manufacturers are replacing conventional batch operations with connected upstream and downstream continuous workflows to improve process efficiency, reduce contamination risks, and shorten production timelines. The integration of single-use bioreactors, continuous chromatography, and real-time process monitoring further enhances manufacturing flexibility and operational efficiency.
High Capital Investment and Stringent Process Validation & Regulatory Transition Restrain Market Expansion
Continuous bioprocessing requires substantial investment in advanced bioreactors, continuous chromatography systems, automation platforms, and process analytical technologies. Integrating these technologies into existing batch-based manufacturing facilities often requires extensive process redesign, equipment validation, and workforce training, increasing implementation costs and timelines. As a result, many small and mid-sized biopharmaceutical manufacturers delay adoption, limiting broader continuous bioprocessing market expansion.
Continuous bioprocessing requires comprehensive process validation, monitoring, and robust control strategies to demonstrate consistent product quality throughout uninterrupted manufacturing operations. Transitioning approved biologics from batch to continuous production also requires extensive comparability studies and regulatory documentation, increasing development time and compliance costs. Consequently, regulatory complexity and lengthy validation requirements continue to restrain widespread adoption of continuous bioprocessing technologies.
Growing Commercialization of Cell Culture Intensification and Expansion of GLP-1 and Next Generation Biologics Manufacturing Offer Growth Opportunities to Market Players
The increasing commercialization of intensified perfusion cell culture and integrated continuous downstream purification is creating new opportunities for continuous bioprocessing solution providers. Biopharmaceutical manufacturers are seeking modular manufacturing platforms that enable rapid scale-up, flexible multi-product production, and improved facility utilization without major infrastructure expansion. This transition is accelerating demand for continuous chromatography, advanced filtration systems, process analytical technologies, and automated control platforms across commercial biologics manufacturing facilities.
The rapid commercialization of GLP-1 therapies, bispecific antibodies, and antibody-drug conjugates is creating significant opportunities for continuous bioprocessing technology providers. These complex biologics require highly productive, flexible, and quality-controlled manufacturing platforms that continuous processing can efficiently support. As next-generation biologics pipelines expand, demand for integrated continuous manufacturing solutions is expected to increase substantially.
Ensuring Process Consistency and Limited Availability of Skilled Workforce Challenges Market Growth
A key challenge for the continuous bioprocessing market is maintaining stable process performance throughout extended manufacturing campaigns. Variations in cell metabolism, nutrient availability, bioreactor conditions, and product quality attributes over prolonged production runs require continuous optimization and advanced process control. Manufacturers must implement sophisticated monitoring strategies and predictive analytics to ensure uninterrupted operations, increasing technical complexity and operational costs.
The transition from batch to continuous bioprocessing requires specialized expertise in automation, process analytical technologies, data analytics, and integrated upstream & downstream operations. However, the availability of professionals with experience in designing, validating, and operating continuous manufacturing systems remains limited. Consequently, biopharmaceutical manufacturers face longer implementation timelines, higher training investments, and slower technology adoption, particularly in emerging biomanufacturing markets.
Based on product, the instruments segment is expected to grow at a CAGR of 17.88% during the forecast period, owing to increasing adoption of continuous bioreactors and integrated process control platforms. Growing demand for real-time monitoring, advanced automation, and scalable manufacturing systems is accelerating deployment across commercial biologics production facilities.
The consumables & reagents segment is expected to grow at a CAGR of around 18.25% during the forecast period due to rising use of single-use flow paths, chromatography resins, and filtration membranes. Frequent replacement requirements and increasing production batches continuously support recurring consumption across biopharmaceutical manufacturing operations.
In 2025, monoclonal antibodies accounted for a share of 35.94% in the continuous bioprocessing market, by application. This is due to high commercial production volumes, established continuous perfusion manufacturing processes, and increasing demand for consistent product quality in therapeutic antibody production worldwide.
The cell and gene therapy segment is expected to grow at a CAGR of 18.30% during the forecast period, driven by increasing adoption of closed continuous processing platforms for sensitive biologics. Expanding personalized therapies and demand for flexible, small-batch manufacturing further accelerate segment expansion.
By end use, pharmaceutical and biotechnology companies accounted for a share of 49.07% in 2025 due to substantial investments in continuous manufacturing infrastructure and biologics process optimization. Strong emphasis on reducing production costs while accelerating commercial product launches further strengthens segment leadership.
The CROs & CMOs segment is expected to grow at a CAGR of 18.73% during the forecast period, driven by increasing outsourcing of biologics manufacturing and process development activities. Rising client demand for flexible manufacturing capacity and specialized continuous processing expertise supports rapid segment growth.
North America: Market Dominance Led by Commercialization of Continuous Bioprocessing Technologies and Increasing Adoption of Continuous Downstream Purification Technologies
The North America continuous bioprocessing market accounted for the largest regional share of 38.65% in 2025, driven by the presence of a highly established biologics manufacturing ecosystem, early commercialization of continuous bioprocessing technologies, and extensive deployment of advanced process analytical technologies. The region also benefits from strong collaboration between biopharmaceutical companies, equipment suppliers, and research institutions, accelerating validation and large-scale implementation of continuous manufacturing platforms.
The US continuous bioprocessing market was valued at USD 130.69 million in 2025, driven by rapid expansion of commercial biologics manufacturing capacity, increasing deployment of continuous production technologies, and growing investments in next-generation biomanufacturing infrastructure. A major example is FUJIFILM Biotechnologies, which inaugurated its USD 3.2 billion Holly Springs, North Carolina facility in September 2025 with 8 × 20,000 L mammalian bioreactors, making it one of North America's largest commercial cell culture manufacturing sites and significantly strengthening regional continuous bioprocessing capabilities.
The continuous bioprocessing market in Canada was valued at USD 18.84 million in 2025, supported by expansion of domestic biologics manufacturing capacity, increasing adoption of continuous downstream purification technologies, and strong public investments in biomanufacturing innovation. Strategic collaborations between Canadian biotechnology companies, contract manufacturers, and research institutions are accelerating commercialization of advanced continuous bioprocessing platforms for vaccines, recombinant proteins, and next-generation biologics.
Asia Pacific: Fastest Growth Driven by Rapid Biomanufacturing Capacity Expansion and Government Support for Biologics Production
The Asia Pacific continuous bioprocessing market is expected to grow at a CAGR of 19.10% during the forecast period, showcasing the fastest regional growth. Growth is supported by the establishment of commercial biomanufacturing facilities, increasing investments in biologics production, and strong government support for domestic biopharmaceutical manufacturing. The region is witnessing growing adoption of continuous manufacturing technologies to improve production efficiency and reduce costs. For example, Samsung Biologics completed Plant 5 in 2025, adding 180,000 L of manufacturing capacity and increasing its total installed capacity to 784,000 L, the largest biologics manufacturing capacity at a single site globally.
The China continuous bioprocessing market was valued at USD 21.05 million in 2025, supported by the expansion of domestic CDMOs, increasing commercialization of monoclonal antibodies and biosimilars, and government initiatives promoting high-end biomanufacturing. WuXi Biologics' integrated manufacturing campuses and continuous investment in advanced perfusion, filtration, and continuous downstream processing technologies are strengthening China's position as a global biologics manufacturing hub.
The India continuous bioprocessing market was valued at USD 11.13 million in 2025, fueled by increasing investments in biosimilar manufacturing, expansion of GMP biologics production facilities, and rising adoption of single-use continuous bioprocessing technologies. The country's growing contract development and manufacturing sector, coupled with government initiatives promoting domestic biopharmaceutical manufacturing, continues to accelerate adoption of continuous manufacturing platforms.
The Japan continuous bioprocessing market was valued at USD 12.84 million in 2025, supported by strong demand for biologics manufacturing, increasing implementation of advanced process analytical technologies, and growing investments in next-generation bioprocess automation. The presence of leading life science companies, established regulatory standards, and continuous innovation in precision biomanufacturing are driving wider adoption of continuous bioprocessing systems across the country.
The continuous bioprocessing market competitive landscape is moderately consolidated, with competition centered among leading bioprocess equipment manufacturers, life sciences companies, and biomanufacturing technology providers. Key players compete through continuous processing innovations, automation capabilities, integrated single-use solutions, and strong partnerships with biopharmaceutical manufacturers. The continuous bioprocessing market ecosystem is driven by increasing biologics production, stringent regulatory requirements, advancements in process analytical technologies, growing adoption of digital manufacturing, and rising demand for scalable, cost-efficient, and flexible bioprocessing solutions that improve manufacturing productivity and product quality.
December 2025: Samsung Biologics announced the planned acquisition of a US manufacturing facility in Rockville, Maryland, expanding its global CDMO manufacturing footprint and strengthening supply chain resilience.
September 2025: Thermo Fisher Scientific completed the acquisition of Solventum's Purification & Filtration business for approximately USD 4.0 billion, strengthening its bioprocessing and filtration portfolio for biologics manufacturing.
August 2025: WuXi Biologics launched the WuXia293 Stable cell line platform to support the development and commercial manufacturing of difficult-to-express biologics, expanding its advanced bioprocessing technology portfolio.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Analyst
Pavan Warade is a Research Analyst with over 4 years of expertise in Technology and Aerospace & Defense markets. He delivers detailed market assessments, technology adoption studies, and strategic forecasts. Pavan’s work enables stakeholders to capitalize on innovation and stay competitive in high-tech and defense-related industries.
We are featured on:
sales@straitsresearch.com